Hanmi Pharm, Ranked No.1 in Outpatient Prescriptions for 3 Consecutive Years

6-Year Cumulative Performance Also Industry No. 1

[Image source=Yonhap News]

[Asia Economy Reporter Kim Ji-hee] Hanmi Pharmaceutical has secured the number one position in domestic outpatient prescription sales for three consecutive years.

Hanmi Pharmaceutical announced on the 22nd that it achieved outpatient prescription sales of 666.5 billion KRW last year, a 2.2% increase compared to the previous year, ranking first in the domestic pharmaceutical industry. Since first taking the top spot in 2018, it has maintained the lead for three consecutive years. In 2018, when it first ranked first, it recorded 603.3 billion KRW.

Hanmi Pharmaceutical explained that this result was due to its differentiated self-developed improved and combination drugs.

In particular, the growth of Rosuzet stood out. Rosuzet, which ranked 9th among domestic prescription drugs with outpatient prescription sales of 81 billion KRW in 2019, rose to 2nd place with sales of 99.1 billion KRW last year, a 22.3% increase. Rosuzet, along with Amozaltan, also ranked within the top 10 in the overall domestic prescription sales product rankings last year. Since its launch, Amozaltan has achieved cumulative sales exceeding 750 billion KRW.

Other self-developed products have also shown continuous growth. Last year, there were a total of 12 products with prescription sales exceeding 10 billion KRW, including Rosuzet, Amozaltan, Esomezol, Amozaltan Plus, Amodipine, Hanmi Tams, Naxozol, Robelito, Hyalumini, Canitil, Labondi, and Fidogle.

Meanwhile, Hanmi Pharmaceutical has achieved a total prescription sales amount of 3.316 trillion KRW over six years since 2015, ranking first among domestic and international pharmaceutical companies.

This content was produced with the assistance of AI translation services.